Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer – results from the MaTox project. 7. Juli 2017 Hurtz, H.-J., Tesch, H., Göhler, T., Hutzschenreuter, U., Harde, J., Kruggel, L., Jänicke, M., Marschner, N., TMK-Group (Tumour Registry Breast Cancer), 2017. Breast Cancer Res Treat. 2017 Jul 5. doi: 10.1007/s10549-017-4365-7 Abstract The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape. Goebell, P.J., Doehn, C., Grüllich, C., Grünwald, V., Steiner, T., Ehneß, R., Welslau, M., 2017. Future Oncol 0(0). doi:10.2217/fon-2017-0083 (epup ahead of print)… Weiterlesen Routine clinical use of nab-paclitaxel for advanced / metastatic breast cancer in Germany: Final results of the prospective observational study NABUCCO. Schroeder, J., Potthoff, K., Salat, C., Soeling, U., Hansen, R., Grebhardt, S., Harde, J., Nusch, A., Marschner, N., 2017. J Clin Oncol 35(suppl; abstr e12555). Weiterlesen